No abstract available
MeSH terms
-
Activating Transcription Factor 3
-
Activating Transcription Factor 4
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Boronic Acids / administration & dosage*
-
Boronic Acids / pharmacology
-
Bortezomib
-
Cyclin-Dependent Kinase 5
-
Cytokines
-
DNA-Binding Proteins
-
Dexamethasone / administration & dosage
-
Drug Discovery
-
Drug Resistance, Neoplasm / genetics*
-
Humans
-
Hydroxamic Acids / administration & dosage
-
Indoles / administration & dosage
-
Kruppel-Like Transcription Factors
-
Molecular Targeted Therapy*
-
Multiple Myeloma / drug therapy*
-
Multiple Myeloma / genetics*
-
Multiple Myeloma / pathology
-
Nicotinamide Phosphoribosyltransferase
-
Oligopeptides / administration & dosage
-
Panobinostat
-
Phosphorylcholine / administration & dosage
-
Phosphorylcholine / analogs & derivatives
-
Proteasome Inhibitors / administration & dosage*
-
Proteasome Inhibitors / pharmacology
-
Proto-Oncogene Proteins c-bcl-2 / metabolism
-
Pyrazines / administration & dosage*
-
Pyrazines / pharmacology
-
Regulatory Factor X Transcription Factors
-
Toyocamycin / administration & dosage
-
Transcription Factors
Substances
-
ATF3 protein, human
-
ATF4 protein, human
-
Activating Transcription Factor 3
-
Boronic Acids
-
Cytokines
-
DNA-Binding Proteins
-
Hydroxamic Acids
-
Indoles
-
KLF9 protein, human
-
Kruppel-Like Transcription Factors
-
Oligopeptides
-
PMAIP1 protein, human
-
Proteasome Inhibitors
-
Proto-Oncogene Proteins c-bcl-2
-
Pyrazines
-
Regulatory Factor X Transcription Factors
-
Transcription Factors
-
Phosphorylcholine
-
Activating Transcription Factor 4
-
perifosine
-
Bortezomib
-
carfilzomib
-
Dexamethasone
-
Panobinostat
-
Nicotinamide Phosphoribosyltransferase
-
nicotinamide phosphoribosyltransferase, human
-
Cyclin-Dependent Kinase 5
-
CDK5 protein, human
-
Toyocamycin